An observational study in Cardiac and Aortic Surgery, Cardiac Anaesthesia and Venous Congestion, sponsored by Medical University of Vienna. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-19.
Sponsored by Medical University of Vienna · Observational
The objective of this study is to assess how fluid resuscitation, in the context of fluid responsiveness, affects the incidence and progression of systemic venous congestion in critically ill cardiac patients. Additionally, the study aims to evaluate the impact on clinical outcomes, with a particular focus on acute kidney dysfunction. This assessment will utilize the VExUS score in conjunction with comprehensive bedside echocardiographic evaluations.
98 studies on the registry are indexed under Hyperemia; 44 are open to participants now.
This study's planned enrollment of 250 is above the median of 100 across 46 observational studies indexed under Hyperemia.
Browse Hyperemia studies →Medical University of Vienna is the lead sponsor of 1,109 studies on the registry; 184 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Cardiac critically ill patients (mainly post cardiac surgery)
Inclusion Criteria:
The VExUS system provides a semi-quantitative assessment of systemic venous congestion by integrating ultrasound evaluations of the inferior vena cava diameter, hepatic vein flow, portal pulsatility, and renal venous flow, offering a practical and comprehensive bedside tool
Venous congestion
Venous congestion as assessed by the VExUS score at ICU admission, and on each of the first seven postoperative days.
Time frame: 7 days
Acute kidney injury
Acute kidney injury (AKI), defined through the KDIGO criteria, within seven and twenty-eight days of ICU admission.
Time frame: Twenty-eight days
No study locations are listed for this record.
Plan to share: Undecided — Data is available upon reasonable request and after the approval of the Steering Committee members.
No publications or documents are linked to this record.
Start is estimated for Sep 2025; primary completion for Sep 2027, 24 months later.
Of 28 observational studies under Hyperemia, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 27. This study's planned 24 months is above that.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Medical University of Vienna →